Company BB Biotech AG

Equities

BION

CH0038389992

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Group companies

Sector

Sales per region

Ratings for BB Biotech AG

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 09:07:47 2024-04-24 am EDT			5-day change	1st Jan Change
41.4 ^CHF	-0.48%		-1.43%	-2.92%

Feb. 14	BB Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 19	BB Biotech Names Successor to Outgoing Chair	MT

BB Biotech AG is a Switzerland-based investment company, which principal activity is to invest in companies active in the biotechnology industry. BB Biotech AG invests mainly in companies operating in such sectors as oncology, infectious diseases, cardiovascular diseases, metabolic diseases and autoimmune diseases. The Companyâs portfolio comprises between 20 and 35 companies and includes such companies as Celgene, Actelion, Vertex Pharmaceuticals, Gilead, Novo Nordisk, Incyte, Isis Pharmaceuticals, Immunogen, Halozyme Therapeutics, Ariad Pharmaceuticals, Biomarin Pharmaceutical, Alexion Pharmaceuticals, Optimer Pharmaceuticals, Achillion Pharmaceuticals, Swedish Orphan Biovitrum, Dendreon, Bavarian Nordic, Lupin, Glenmark Pharmaceuticals, Strides Arcolab, Endocyte, Probiodrug, and Idenix Pharmaceuticals.

Number of employees: 10

CHF in Million	2022	Weight	2023	Weight	Delta
Biotechnology 100.0 %	1	100.0 %	1	100.0 %	-57.97%

CHF in Million	2022	Weight	2023	Weight	Delta
Switzerland 100.0 %	1	100.0 %	1	100.0 %	-57.97%

Managers	Title	Age	Since
Daniel Koller CIO	Chief Investment Officer	54	03-12-31
Tanja Chicherio		-	-
Silvia Siegfried-Schanz		-	-
Felicia Flanigan PRN	Corporate Officer/Principal	-	03-12-31

Members of the board	Title	Age	Since
Clive Meanwell BRD	Director/Board Member	67	03-12-31
Mads Krogsgaard Thomsen BRD	Director/Board Member	63	19-12-31
Thomas von Planta CHM	Chairman	63	19-03-20
Pearl Shirley Huang BRD	Director/Board Member	67	22-03-16
Laura Hamill BRD	Director/Board Member	60	22-03-16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	55,400,000	53,870,953 ( 97.24 %)	554,000 ( 1.000 %)	97.24 %

Name	Equities	%	Valuation
Alpine Select AG (Investment Management) 4.116 %	2,280,540	4.116 %	115 M CHF
Union Investment Privatfonds GmbH 2.251 %	1,246,800	2.251 %	63 M CHF
Erich Hunziker 1.729 %	957,884	1.729 %	48 M CHF
LBBW Asset Management Investmentgesellschaft mbH 1.426 %	790,000	1.426 %	40 M CHF
Cominvest Asset Management GmbH 1.058 %	586,000	1.058 %	30 M CHF
BB BIOTECH AG 1.000 %	554,000	1.000 %	28 M CHF
Union Investment Institutional GmbH 0.8574 %	475,000	0.8574 %	24 M CHF
Eurizon Capital SGR SpA 0.7411 %	410,546	0.7411 %	21 M CHF
Goldman Sachs Advisors BV 0.6047 %	335,000	0.6047 %	17 M CHF
BayernInvest Kapitalverwaltungsgesellschaft mbH 0.5860 %	324,645	0.5860 %	16 M CHF

Name	Equities	%	Valuation
IONIS PHARMACEUTICALS, INC. 5.89%	8,590,000	5.89%	372,376,500 $
SAGE THERAPEUTICS, INC. 5.83%	3,505,000	5.83%	65,683,700 $
ANNEXON, INC. 5.20%	4,682,290	5.20%	33,572,019 $
BB BIOTECH AG 1.00%	554,000	1.00%	28,016,766 $
WAVE LIFE SCIENCES LTD. 3.68%	4,494,458	3.68%	27,730,806 $
MOLECULAR TEMPLATES, INC. 23.81%	1,279,820	23.81%	2,866,797 $

BB Biotech AG

Schwertstrasse 6

8200, Schaffhausen

+41 44 2676700

http://www.bbbiotech.com

Name	Category and Sector
Biotech Focus NV
Biotech Invest NV
Biotech Target NV Biotech Target NV MiscellaneousMiscellaneous Part of BB Biotech AG, Biotech Target NV is a Dutch company that specializes in the offices of other holding companies. The private company is located in the Netherlands.	Miscellaneous
Biotech Growth NV Biotech Growth NV Financial ConglomeratesFinance Part of BB Biotech AG, Biotech Growth NV is a Dutch company that provides blank check company services. The private company is located in the Netherlands.	Financial Conglomerates

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

41.6 CHF

Average target price

47.7 CHF

Spread / Average Target

+14.66%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BB BIOTECH AG	-3.16%	2.51B
IQVIA HOLDINGS INC.	+3.13%	43.43B
LONZA GROUP AG	+47.64%	41.69B
MODERNA, INC.	+8.49%	41.31B
CELLTRION, INC.	-10.82%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.26%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	12.33B
MEDPACE HOLDINGS, INC.	+32.83%	12.59B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.03B

Other Biotechnology & Medical Research